Yashutosh Joshi1,2,3, Marie-Cecile Bories4, Nadia Aissaoui5,6, Jean-Michel Grinda4, Alain Bel4, Christian Latremouille4,6, Jérôme Jouan4,6. 1. St Vincent's Hospital, Sydney, NSW, Australia. 2. Western Sydney University, Blacktown Clinical School, Sydney, NSW, Australia. 3. St Vincent's Clinical School UNSW, Sydney, NSW, Australia. 4. Hôpital Européen Georges Pompidou, Département de Chirurgie Cardio-vasculaire, Assistance Publique Hôpitaux de Paris, Paris, France. 5. Hôpital Européen Georges Pompidou, Service de Réanimation médicale, Assistance Publique Hôpitaux de Paris, Paris, France. 6. Université Paris-Descartes, Paris, France.
Abstract
OBJECTIVES: Right ventricular failure after left ventricular assist device (LVAD) insertion is associated with significant mortality and morbidity. Mechanical support options include right ventricular assist devices, venoarterial extracorporeal membrane oxygenation (ECMO) and venopulmonary artery ECMO, the latter often involving central cannulation. We sought to evaluate the feasibility and early outcomes of a truly percutaneous venopulmonary artery (pVPA) ECMO strategy, with the potential advantage of bedside removal once weaned. METHODS: Data from a single tertiary centre were reviewed retrospectively from January 2014 to January 2019. During this time, 54 patients underwent LVAD insertion, with 19 requiring mechanical support for right ventricular failure. Among them, 10 patients received pVPA ECMO. Implantation of the pVPA ECMO was performed under transoesophageal echocardiography and fluoroscopy guidance, with an inflow cannula placed in the right atrium via the right femoral vein and an outflow cannula placed in the left pulmonary artery (PA) via the right internal jugular vein. RESULTS: Cannula insertion was 100% successful with no need for repositioning. Eight patients (80%) were able to be successfully weaned (at the bedside); 6 were discharged from the hospital and there were no cases of early sepsis, mediastinitis or thromboembolism. At follow-up, 5 patients had received transplants (50%), with 1 on LVAD support as destination therapy (10%). Survival was 60 ± 15% and 50 ± 16% at 6 and 12 months, respectively. CONCLUSIONS: pVPA ECMO is 100% technically feasible and is an efficient method for temporary right ventricular support after LVAD insertion with the advantage of simple bedside removal and avoidance of a PA graft remnant in the chest cavity.
OBJECTIVES: Right ventricular failure after left ventricular assist device (LVAD) insertion is associated with significant mortality and morbidity. Mechanical support options include right ventricular assist devices, venoarterial extracorporeal membrane oxygenation (ECMO) and venopulmonary artery ECMO, the latter often involving central cannulation. We sought to evaluate the feasibility and early outcomes of a truly percutaneous venopulmonary artery (pVPA) ECMO strategy, with the potential advantage of bedside removal once weaned. METHODS: Data from a single tertiary centre were reviewed retrospectively from January 2014 to January 2019. During this time, 54 patients underwent LVAD insertion, with 19 requiring mechanical support for right ventricular failure. Among them, 10 patients received pVPA ECMO. Implantation of the pVPA ECMO was performed under transoesophageal echocardiography and fluoroscopy guidance, with an inflow cannula placed in the right atrium via the right femoral vein and an outflow cannula placed in the left pulmonary artery (PA) via the right internal jugular vein. RESULTS: Cannula insertion was 100% successful with no need for repositioning. Eight patients (80%) were able to be successfully weaned (at the bedside); 6 were discharged from the hospital and there were no cases of early sepsis, mediastinitis or thromboembolism. At follow-up, 5 patients had received transplants (50%), with 1 on LVAD support as destination therapy (10%). Survival was 60 ± 15% and 50 ± 16% at 6 and 12 months, respectively. CONCLUSIONS: pVPA ECMO is 100% technically feasible and is an efficient method for temporary right ventricular support after LVAD insertion with the advantage of simple bedside removal and avoidance of a PA graft remnant in the chest cavity.
Authors: Mark B Anderson; James Goldstein; Carmelo Milano; Lynn D Morris; Robert L Kormos; Jay Bhama; Navin K Kapur; Aditya Bansal; Jose Garcia; Joshua N Baker; Scott Silvestry; William L Holman; Pamela S Douglas; William O'Neill Journal: J Heart Lung Transplant Date: 2015-09-08 Impact factor: 10.247
Authors: Nicholas C Dang; Veli K Topkara; Michelle Mercando; Joy Kay; Kurt H Kruger; Michael S Aboodi; Mehmet C Oz; Yoshifumi Naka Journal: J Heart Lung Transplant Date: 2005-12-09 Impact factor: 10.247
Authors: Stavros G Drakos; Lindsay Janicki; Benjamin D Horne; Abdallah G Kfoury; Bruce B Reid; Stephen Clayson; Kenneth Horton; Francois Haddad; Dean Y Li; Dale G Renlund; Patrick W Fisher Journal: Am J Cardiol Date: 2010-02-13 Impact factor: 2.778
Authors: Jennifer Cowger Matthews; Todd M Koelling; Francis D Pagani; Keith D Aaronson Journal: J Am Coll Cardiol Date: 2008-06-03 Impact factor: 24.094
Authors: Koji Takeda; Yoshifumi Naka; Jonathan A Yang; Nir Uriel; Paolo C Colombo; Ulrich P Jorde; Hiroo Takayama Journal: ASAIO J Date: 2013 Nov-Dec Impact factor: 2.872
Authors: Roberto Lorusso; Giuseppe Maria Raffa; Samuel Heuts; Valeria Lo Coco; Paolo Meani; Ehsan Natour; Elham Bidar; Thijs Delnoij; Antonio Loforte Journal: Interact Cardiovasc Thorac Surg Date: 2020-02-01